Mitsubishi UFJ Trust & Banking Corp Reduces Position in DaVita Inc. $DVA

Mitsubishi UFJ Trust & Banking Corp cut its position in DaVita Inc. (NYSE:DVA) by 13.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 118,173 shares of the company’s stock after selling 18,689 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.17% of DaVita worth $15,702,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. NewEdge Advisors LLC boosted its holdings in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares during the period. V Square Quantitative Management LLC lifted its position in shares of DaVita by 22.8% during the 2nd quarter. V Square Quantitative Management LLC now owns 2,422 shares of the company’s stock valued at $345,000 after buying an additional 449 shares in the last quarter. Truist Financial Corp lifted its holdings in DaVita by 1.9% during the second quarter. Truist Financial Corp now owns 8,646 shares of the company’s stock valued at $1,232,000 after purchasing an additional 163 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its stake in DaVita by 485.5% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 44,809 shares of the company’s stock valued at $6,383,000 after buying an additional 37,156 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DVA stock opened at $105.66 on Wednesday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $179.60. The company has a 50 day moving average price of $114.16 and a 200 day moving average price of $125.81. The stock has a market capitalization of $7.46 billion, a P/E ratio of 10.88, a price-to-earnings-growth ratio of 0.66 and a beta of 0.99.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.59 EPS. On average, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Barclays reduced their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. UBS Group reissued a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Truist Financial lowered their price objective on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research report on Monday, January 5th. Finally, Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.